Clinical Trial Update: Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating paclitaxel with BKM120 before surgery in stage II/III estrogen receptor-positive, HER2-negative breast cancer has been withdrawn. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BKM120 (Buparlisib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Breast Neoplasms | Phase 2 | Status: WITHDRAWN